Skip to main content

Table 2 Microtissue maintenance and NM treatment in the singular and repeated exposure experiments over a period of 15 days

From: Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model

Single exposure End-points investigated
Treatment 1 – 0 hr (day 0) -
Change medium – 24 hr (day 1) AK assay, cytokine secretion, albumin
Change medium – 72 hr (day 3) Albumin
Change medium – 168 hr (day 7) AK assay, cytokine secretion
Change medium – 216 hr (day 9) Albumin
Change medium – 264 hr (day 11) -
Change medium – 336 hr (day 14) -
Change medium – 360 hr (day 15) AK assay, cytokine secretion, lipid peroxidation, DNA damage, albumin
Multiple exposure End-points investigated
Treatment 1 – 0 hr (day 0) -
Change medium – 24 hr (day 1) – 48 hr recovery period AK assay, cytokine secretion
Treatment 2 – 72 hr (day 3) AK assay, cytokine secretion, albumin
Change medium – 96 hr (day 4) - 48 hr recovery period AK assay, cytokine secretion, albumin
Treatment 3 – 144 hr (day 6) AK assay, cytokine secretion
Change medium – 168 hr (day 7) - 48 hr recovery period AK assay, cytokine secretion, albumin
Treatment 4 – 216 hr (day 9) AK assay, cytokine secretion, albumin
Change medium – 240 hr (day 10) - 48 hr recovery period AK assay, cytokine secretion, albumin
Treatment 5 – 288 hr (day 12) -
Change medium – 312 hr (day 13) AK assay, cytokine secretion
Change medium – 360 hr (day 15) Lipid peroxidation, DNA damage, albumin